Background
==========

Individuals with diabetes mellitus have a greater risk of cardiovascular events than those without^[@bib1])^. Patients with diabetes frequently experience restenosis after coronary angioplasty, even after intervention with currently available drug-eluting stents^[@bib2])^. Consequently, the aim of glycemic control is not only the lowering of the blood glucose level but also improving the quality of life and mortality by preventing the occurrence and progression of vascular complications. Therefore, it is important to investigate the vascular-protective effects of anti-diabetic agents.

Incretin therapy, which includes glucagon-like peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, has been a focus because of its tissue-protective effects beyond lowering blood glucose levels^[@bib3])^, such as cardiovascular protection^[@bib4])^, anti-hepatic steatosis^[@bib5])^, and anti-Alzheimer\'s disease^[@bib6])^. Previously, we have reported the vascular-protective effects of the GLP-1R agonist Exendin-4 (Ex-4), including the attenuation of atheroma formation in apoE-deficient mice by inhibiting NF*κ*B activation in macrophages^[@bib7])^ and the reduction of neointima formation after vascular injury by inhibiting vascular smooth muscle cell (VSMC) proliferation^[@bib8])^. Furthermore, we have recently demonstrated the anti-cancer effect of Ex-4 using a prostate cancer model^[@bib9],\ [@bib10])^. In addition, we reported that the DPP-4 inhibitor linagliptin attenuates neointima formation by not only incretin effects but also anti-oxidative stress effects^[@bib11])^.

The nuclear receptor superfamily has been recognized as one of key regulators of the inflammatory response and VSMC proliferation in atherosclerosis and vascular diseases^[@bib12])^. Although much attention is focused on peroxisome proliferator-activated receptors (PPARs)^[@bib13])^ and liver X receptors (LXRs)^[@bib14])^ as therapeutic targets, we have investigated the role of NR4A orphan nuclear receptors, particularly NR4A3 neuron-derived orphan receptor 1 (NOR1), in atherosclerosis and vascular diseases^[@bib15])^. NOR1 was identified in primary cultured rat fetal forebrain cells undergoing apoptosis^[@bib16])^. In human coronary arteries, NOR1 is expressed in VSMCs migrating into atherosclerotic lesions, but not in normal vessels, and mitogenic stimulation induces NOR1 expression via extracellular signal-regulated kinase (ERK)-mitogen-activated protein kinase (MAPK) and cAMP-responsive element-binding protein (CREB) phosphorylations^[@bib17])^. NOR1 has a pivotal role in VSMC proliferation, and NOR1 deficiency reduces neointima formation after vascular injury by inhibiting G1--S phase entry of cell cycle progression in VSMCs, as we reported previously^[@bib18],\ [@bib19])^. However, currently, there are no reports that have elucidated the interaction between GLP-1 and NOR1 in VSMCs. In the present study, we demonstrate that Ex-4 attenuates NOR1 expression both *in vivo* and *in vitro* in VSMCs.

Methods
=======

Animals
-------

The study protocol was reviewed and approved by the Animal Care and Use Committee of Fukuoka University. Six-week-old male 129X1/SvJ mice were purchased from Japan SLC, Inc. (Sizuoka, Japan). All mice were housed in a polycarbonate cage with a wooden chip mat on the floor, and water was available *ad libitum*. All mice were fed normal chow (20% protein, 70% carbohydrate, and 10% fat; D12450B, Research Diet, New Brunswick, NJ). The animal room was kept in a 12-h light/dark cycle at a constant temperature (22°C ± 1°C) and relative humidity of 55% ± 5% throughout the experimental period. Mice were divided into the saline-control (*n* = 9) group, Ex-4 low-dose (300 pmol/kg body weight/day, *n* = 10)-treated group, and Ex-4 high-dose (24 nmol/kg body weight/day, *n* = 10)-treated group. At 7 weeks of age, a miniosmotic pump (ALZEST, model 1004; DURECT, Cupertino, CA) was implanted under the skin of the back of each mouse after local anesthesia. Saline or Ex-4 (Sigma-Aldrich, Tokyo) was infused via the osmotic pump that continuously delivered the solution for up to 4 weeks. Endothelial denudation injuries were induced in the femoral artery at 8 weeks of age, followed by the evaluation of neointimal formation at 12 weeks of age.

Animals Fed High-Fat Diet
-------------------------

Seven-week-old male 129X1/SvJ mice were fed high-fat diet (20% protein, 20% carbohydrate, and 60% fat, D12492, Research Diet) and divided into the saline-control (*n* = 5) group, Ex-4 low-dose (300 pmol/kg body weight/day, *n* = 5)-treated group, and Ex-4 high-dose (24 nmol/kg body weight/day, *n* = 5)-treated group. Endothelial denudation injuries were induced in the femoral artery at 8 weeks of age. Mice were euthanized at 12 weeks of age and femoral arteries were isolated for tissue analysis.

Guidewire-Induced Endothelial Denudation Injury
-----------------------------------------------

Mouse femoral artery endothelial denudation injuries were established, as we previously reported^[@bib8],\ [@bib11],\ [@bib18])^, in 129X1/SvJ mice treated as control (saline, *n* = 9), Ex-4 low-dose (300 pmol/kg/day, *n* = 10), and Ex-4 high-dose (24 nmol/kg/day, *n* = 10) groups at 8 weeks of age, as described previously^[@bib8])^. Briefly, endovascular injuries were induced by four passages of a 0.25-mm SilverSpeed-10 hydrophilic guidewire (Micro Therapeutics Inc., Irvine, CA, USA) into the left femoral artery. Mice were euthanized at 4 weeks after injury, and femoral arteries were isolated for tissue analysis.

Tissue Preparation and Morphometry
----------------------------------

Following sacrifice, mice were perfused via a cannula in the left ventricle with phosphate-buffered saline for 5 min, followed by 4% paraformaldehyde for 30 min at 100 cm H~2~O. The femoral arteries were embedded in paraffin, cut into 5-µm sections, and prepared for Elastica van Gieson and immunofluorescence staining. Serial sections of the 0.5-mm proximal region from the incision site of the wire insertion were evaluated using Elastica van Gieson stain kit (ab150667, Abcam, Cambridge, UK) to visualize the internal elastic lamina, as described previously^[@bib11])^. Specimens were viewed under a microscope (BZ9000; Keyence, Tokyo, Japan) connected to a computer. Intimal and medial areas were measured by computerized morphometry using BZ-II analyzer software (Keyence, Tokyo, Japan). Intimal hyperplasia was defined as neointimal layer formation medial to the internal elastic lamina. The medial area represents the area between external and internal elastic laminae. The intima-to-media ratio was calculated as the intimal area divided by the media area, as described previously^[@bib8],\ [@bib11])^.

Immunohistochemistry
--------------------

Paraffin sections were incubated with a Cy-3-conjugated α-smooth muscle actin antibody (C6198, Sigma-Aldrich). Serial sections were incubated with anti-NOR1 (HPA043360, Sigma-Aldrich) and anti-PCNA (sc-9857; Santa Cruz, CA) antibodies. Sections analyzed for NOR1 were subsequently incubated with Alexa Fluor 647 goat anti-rabbit IgG (A21246, Life technologies), and sections analyzed for PCNA were subsequently incubated with Alexa Fluor 488 donkey anti-goat IgG (A11055, Life technologies). Sections were counterstained with DAPI and visualized using confocal microscopy.

Insulin Measurements
--------------------

Insulin concentrations in mouse serum were measured using Ultra-Sensitive Mouse Insulin ELISA Kit (Morinaga Institute of Biological Science, Inc. Kanagawa, Japan), according to the manufacturer\'s protocol.

Cell Culture
------------

Human aortic smooth muscle cells were purchased from Lonza (Allendale, NJ) and maintained in smooth muscle basal medium supplemented with 5% fetal bovine serum (FBS), hEGF, insulin, hFGF-B, and gentamicin/amphotericin-B (SmGM-2 SingleQuots; Lonza), as per the manufacturer\'s instructions, and rat aortic smooth muscle cells were purchased from Lonza and maintained in Dulbecco\'s modified Eagle medium supplemented with 10% FBS. Cells were grown to 60%--70% confluence, serum-deprived for at least 12 h, pretreated with 0.1--10 nM Ex-4 or saline for 12 h, and stimulated with FBS at a final concentration of 10%. Cells were used between passages three and six for the experiments, and individual experiments were repeated at least three times with different preparations of cells.

Western Blot Analysis
---------------------

Western blotting was performed, as described previously^[@bib9],\ [@bib10])^. The following primary antibodies were used: NOR1 (TA804872, ORIGENE), phosphop44/42 MAPK (Thr202/Tyr204) (\#9101; Cell Signaling), p44/42 MAPK (\#9102; Cell Signaling), phospho-CREB (Ser133) (\#9198; Cell Signaling), CREB (\#9197; Cell Signaling), phospho-Akt (Ser473) (\#4058; Cell Signaling), Protein kinase B (Akt) (\#9272; Cell Signaling), phospho-mTOR (Ser2448) (\#2971; Cell Signaling), mTOR (\#2983; Cell Signaling), p27 Kip1 (\#3686; Cell Signaling), and GAPDH (sc-20357; Santa Cruz).

Reverse Transcription (RT) and Quantitative Real-Time PCR
---------------------------------------------------------

RT and quantitative real-time PCR were performed, as described previously^[@bib9],\ [@bib10])^. mRNA from human aortic SMCs was isolated using RNeasy Mini Kits (Qiagen, Venlo, the Netherlands) and reverse transcribed into cDNA. PCRs were performed using Light Cycler 2.0 (Roche, Basel, Switzerland) and SYBR Premix Ex Taq™ II (Takara, Otsu, Japan). Each sample was analyzed in triplicate and normalized against TATA binding protein (*TBP*) mRNA expression. The following primer sequences were used: human TBP, 5′-TGCTGCGGTAATCATGAGGATA-3′ (forward), 5′-TGAAGTCCAAGAACTTAGCTGGAA-3′ (reverse); human NOR1, 5′-CCCCTCCAGGTTCCAGTTAT-3′ (forward), 5′-ATTTGGTACACGCAGGAAGG-3′ (reverse); human Skp2, 5′-ACACTGCAAAAGCCCAGTTG-3′ (forward), 5′-TGCAGAATGAAGGCAAAGGG-3′ (reverse).

Plasmids, Transient Transfections, and Luciferase Assay
-------------------------------------------------------

To evaluate NOR1 transcriptional activity, the luciferase reporter assay was performed in rat aortic SMCs (Lonza) transiently transfected with pGL3-MMTV or NOR1-LUC reporter constructs. Briefly, rat aortic SMCs were transfected for 24 h with 0.5 µg of reporter DNA using FuGENE HD Transfection Reagent (Roche). Next, cells were maintained under serum deprivation for 36 h, pretreated with or without 10 nM Ex-4 for 12 h, and then stimulated with FBS for 12 h. Luciferase activity was assayed using Dual-Luciferase Reporter Assay (Promega, Madison, WI, USA). Transfection efficiency was normalized to *Renilla* luciferase activity generated by co-transfection of cells with 10 ng/well pRL-SV40 (Promega). NOR1 promoter constructs were provided by Dr. Naganari Ohkura (Osaka University, Osaka, Japan).

Cell Cycle Analysis Using Flow Cytometry
----------------------------------------

Human aortic SMCs were seeded in 60-mm dishes at a density of 1 × 10^5^ cells/ml. Cells were grown to 60%--70% confluence, serum-deprived for 36 h, pretreated with 10 nM Ex-4 or saline for 12 h, stimulated with FBS for 30 h. Cell cycle analysis was performed using Cycletest™ Plus DNA reagent kit (BD Biosciences), as per the manufacturer\'s instructions, and a BD FACSVerse (BD Biosciences, Franklin Lakes, NJ, USA). FlowJo (Tree Star, Inc., OR, USA) was used to analyze the flow cytometry data.

Statistical Analysis
--------------------

Results are expressed as mean ± SEM. All statistical analyses were performed using GraphPad Prism software (version 7.0; GraphPad Software, SD, USA). Unpaired *t* -tests and one- or two-way ANOVA were performed for statistical analysis, as appropriate. *P*-values \< 0.05 were considered statistically significant.

Results
=======

Exendin-4 Attenuates Neointima Formation After Vascular Injury in Non-Diabetic Mice
-----------------------------------------------------------------------------------

129X1/SvJ mice were treated with the control (saline), low-dose Ex-4, or high-dose Ex-4 from 7 to 12 weeks of age. Mouse femoral artery endothelial denudation injuries were established at 8 weeks of age in all groups, and neointima formation was evaluated at 12 weeks of age. Endothelial denudation injury in control mice resulted in considerable neointima formation. As depicted in **[Fig. 1A](#F1){ref-type="fig"}**, elastic staining revealed the reduction of neointima formation after vascular injury. Quantitative analysis by measuring squares of the intima, media, and intima-to-media (I/M) ratio suggested that Ex-4 reduced neointima formation after vascular injury in a dose-dependent manner (**[Fig. 1B](#F1){ref-type="fig"}**). However, statistical significances were not achieved (**[Table 1](#T1){ref-type="table"}**). As shown in **[Table 2](#T2){ref-type="table"}**, although high-dose Ex-4 significantly decreased mouse body weight, the blood glucose level and serum insulin concentration were not changed by Ex-4 treatment because the mice were not diabetic, suggesting that the reduction of neointima formation by Ex-4 was independent of the Ex-4 effect on glucose metabolism.

![Neointima formation after vascular injury in control and Ex-4-treated mice.\
Endothelial denudation injuries were induced in the left femoral artery of control (*n* = 9) mice, Ex-4 low-dose (*n* = 9)-treated mice, and Ex-4 high-dose (*n* = 10)-treated mice. (A) Tissues were evaluated by staining with Elastica van Gieson to visualize the internal elastic lamina (magnification, ×200). (B) The area of the intima, media, and intima/media was calculated for each group. One-way ANOVA was performed to calculate statistical significance. Data are mean ± SEM.](jat-26-183-g001){#F1}

###### Neointima formation in exendin-4 (Ex-4)-treated mice at 12 weeks of age following guidewire-induced endothelial denudation injury.

  ---------------------------------------------------------------------------
                   Control            Ex-4\               Ex-4\
                                      Low dose            High dose
  ---------------- ------------------ ------------------- -------------------
  Intima (µm^2^)   36511.8 ± 9621.7   23830.0 ± 4583.6\   14284.1 ± 3801.2\
                                      (*P* = 0.24)        (*P* = 0.07)

  Media (µm^2^)    16049.2 ± 2385.1   13948.9 ± 1235.0\   10338.5 ± 985.9\
                                      (*P* = 0.48)        (*P* = 0.06)

  I/M ratio        2.12 ± 0.37        1.70 ± 0.42\        1.28 ± 0.31\
                                      (*P* = 0.42)        (*P* = 0.12)
  ---------------------------------------------------------------------------

One-way ANOVA was performed to calculate statistical significance. Data are expressed as the mean ± SEM.

*P*-values refer to comparisons with the control.

###### Characteristics of exendin-4 (Ex-4)-treated mice at 12 weeks of age following guidewire-induced endothelial denudation injury.

  -------------------------------------------------------------------------------------------------------------------------------------
                           Control       Ex-4\         Ex-4\
                                         Low dose      High dose
  ------------------------ ------------- ------------- --------------------------------------------------------------------------------
  Body weight (g)          28.1 ± 0.6    28.5 ± 0.3    26.3 ± 0.5[\*](#tf1){ref-type="table-fn"}, ^[\#\#](#tf2){ref-type="table-fn"}^

  Plasma glucose (mg/dl)   150.4 ± 4.0   150.0 ± 3.4   137.1 ± 8.2

  Serum insulin (ng/ml)    0.64 ± 0.07   0.73 ± 0.08   0.47 ± 0.09
  -------------------------------------------------------------------------------------------------------------------------------------

One-way ANOVA was performed to calculate statistical significance. Data are expressed as the mean ± SEM.

*P* \< 0.05 compared with the control.

*P* \< 0.01 compared with low-dose Ex-4.

Exendin-4 Decreases VSMC Proliferation and NOR1 Expression in the Neointima
---------------------------------------------------------------------------

To confirm that cells occupying the neointima after vascular injury were VSMCs, we next performed immunohistochemistry using VSMC marker *α*-smooth muscle cell actin. As depicted in **[Fig. 2](#F2){ref-type="fig"}**, all cells located in the neointima were VSMC (**[Fig. 2A](#F2){ref-type="fig"}**) in all groups. To examine whether Ex-4 decreased the number of cells occupying neointima formation, we counted cells in the intima and media areas. As shown in **[Fig. 2B](#F2){ref-type="fig"}**, Ex-4 decreased the cell number in the neointima and the I/M ratio in a dose-dependent manner. Compared with the control, significant reduction in the cell number was achieved in the high-dose Ex-4 group. To further examine whether Ex-4 decreased NOR1 expression in migrating VSMCs after vascular injury, we next conducted NOR1 immunohistochemistry using injured mouse vessels. As depicted in **[Fig. 2C](#F2){ref-type="fig"}**, profound NOR1 expression with nuclear localization was detected in non-Ex-4-treated control vessels. However, NOR1 expression was dramatically decreased in Ex-4-treated mouse vessels. Finding NOR1-positive cells in the neointima suggested that Ex-4 significantly and dose-dependently decreased NOR1-positive VSMCs (**[Fig. 2D](#F2){ref-type="fig"}**). Interestingly, in parallel with the reduction of NOR1 expression by Ex-4 in VSMCs, Ex-4 significantly and dose-dependently decreased cell proliferation marker PCNA-positive cells (**[Fig. 2C, E](#F2){ref-type="fig"}**). These data suggest that Ex-4 decreased proliferating VSMCs in the neointima after vascular injury, which was associated with the reduction of NOR1 expression *in vivo*.

![Ex-4 suppresses cell growth after vascular injury and expression of NOR1 and PCNA in VSMCs.\
(A) Sections were subjected to immunohistochemistry for αSMA (red) and counterstained with DAPI to visualize nuclei (blue). Magnification, ×630. (B) Total cell count of the intima and media. One-way ANOVA was performed to calculate statistical significance. Data are mean ± SEM. \**P* \< 0.05 vs. control (C) Representative immunofluorescence image of injured femoral arteries showing NOR1 (cyan) and PCNA (green). Magnification, ×630. (D) (E) NOR1- and PCNA-positive cells were quantified by analyzing the fraction of stained cells to the total number of nuclei (Control, *n* = 7; Ex-4 LD, *n* = 8; and Ex-4 HD, *n* = 6). Values are expressed as the percentage of positive cells. One-way ANOVA was performed to calculate statistical significance. \**P* \< 0.05 vs. control, \*\**P* \< 0.01 vs. control.](jat-26-183-g002){#F2}

Exendin-4 Decreases Serum-Induced NOR1 Expression Via GLP-1R
------------------------------------------------------------

Next, we examined whether Ex-4 inhibited NOR1 expression *in vitro* using primary cultured VSMCs. Compatible with our previous reports using rat^[@bib17])^ and mouse^[@bib18])^ VSMCs, NOR1 expression was also negligible in serum-deprived quiescent human VSMCs, and serum stimulation dramatically and promptly induced NOR1 protein (**[Fig. 3A](#F3){ref-type="fig"}**) and mRNA (**[Fig. 3B](#F3){ref-type="fig"}**) expression. Interestingly, after pretreatment with Ex-4, serum-induced NOR1 expression was significantly decreased in a dose-dependent manner (**[Fig. 3A, B](#F3){ref-type="fig"}**). To elucidate whether Ex-4 decreased NOR1 expression by inhibiting NOR1 promoter activity, we next conducted a luciferase assay using NOR1 promoter-Luc construct transfected into rat VSMCs. As shown in **[Fig. 3C](#F3){ref-type="fig"}** shows, serum-induced NOR1 promoter activity was significantly reduced by 10 nM Ex-4 pretreatment, suggesting that Ex-4 decreased NOR1 expression by inhibiting NOR1 promoter activity. However, the canonical pathway of GLP-1R is mediated via cAMP-protein kinase A (PKA) activation. As shown in **[Fig. 3D](#F3){ref-type="fig"}**, co-incubation with GLP-1R antagonist Exendin 9--39 (Ex9--39) and PKA inhibitor PKI cancelled the reduction of NOR1 gene expression by Ex-4. These data suggest that Ex-4 decreased serum-induced NOR1 promoter activation and gene expression via GLP-1R activation and its downstream canonical signaling pathway.

![FBS-induced NOR1 expression is suppressed by Ex-4 pretreatment *in vitro*.\
(A) Serum-deprived human aortic SMCs were stimulated with 10% FBS with 0--10 nM Ex-4 pretreatment. NOR1 protein expression was analyzed at 6 h after FBS stimulation by western blotting. (B) FBS-induced NOR1 mRNA expression was analyzed at 2 h after FBS stimulation with 0--10 nM Ex-4 pretreatment by qRT-PCR. One-way ANOVA was performed to calculate statistical significance. Data are mean ± SEM. \**P* \< 0.05 vs. FBS(+) 0 nM Ex-4, \*\**P* \< 0.01 vs. FBS(+) 0 nM Ex-4. (C) Rat aortic SMCs were transiently transfected with 1.7 kb NOR1 promoter constructs. Serum-deprived cells were pretreated with or without 10 nM Ex-4 and then stimulated with 10% FBS for 12 h. Following stimulation, cells were harvested and luciferase activities were analyzed. Statistical significance was calculated using unpaired *t* -tests. Data are mean ± SEM. \**P* \< 0.05 vs. Control FBS(+). (D) Serum-deprived SMCs were treated with 10 nM Ex-4 or PBS and pretreated for 30 min with or without 100 nM Exendin (9--39) or 10 µM PKI and subsequently stimulated with FBS at a final concentration of 10%. After 2 h of stimulation, NOR1 mRNA expression was determined. One-way ANOVA was performed to calculate statistical significance. Data are mean ± SEM. \**P* \< 0.05 vs. FBS(+) control, ^\#^*P* \< 0.05 vs. FBS(+) Exendin (9--39).](jat-26-183-g003){#F3}

Exendin-4 Inhibits Serum-Induced ERK-MAPK and CREB Phosphorylations
-------------------------------------------------------------------

In our previous report, mitogenic stimulation induced NOR1 expression via ERK-MAPK and CREB phosphorylations^[@bib17])^. Next, we examined the effect of Ex-4 on ERK-MAPK and CREB phosphorylations in human VSMCs by western blotting. As shown in **[Fig. 4A](#F4){ref-type="fig"}**, pretreatment with 10 nM Ex-4 significantly decreased serum-induced phosphorylation of ERKMAPK. Furthermore, serum-induced CREB phosphorylation was decreased by Ex-4 pretreatment (**[Fig. 4B](#F4){ref-type="fig"}**). These data suggest that Ex-4 decreased NOR1 expression via the inhibition of ERK-MAPK-CREB signals in VSMCs. In addition, we examined other VSMC growth signals, protein kinase B (Akt) and mammalian target of rapamycin (mTOR). As shown in **[Fig. 4C](#F4){ref-type="fig"}**, Ex-4 did not attenuate serum-induced Akt phosphorylation. However, small but significant attenuation of serum-induced mTOR phosphorylation was observed after Ex-4 treatment (**[Fig. 4C](#F4){ref-type="fig"}**).

![Ex-4 inhibits FBS-induced phosphorylations of p44/42 MAPK, CREB, and mTOR.\
Serum-deprived human aortic SMCs were preincubated with vehicle or 10 nM Ex-4 for 12 h and stimulated with 10% FBS for 15 min. Whole cell lysates were analyzed for phosphorylated p44/42 MAPK (A) and Ser-133-phosphorylated CREB (B). Cohybridization for total p44/42 MAPK and total CREB was used as control. Statistical significance was calculated using unpaired *t*-tests. Data are mean ± SEM. \**P* \< 0.05 vs. FBS(+) Ex-4(−). (C) Serum-deprived human aortic SMCs were preincubated with vehicle or 10 nM Ex-4 for 12 h and stimulated with 10% FBS for the indicated times. Whole cell lysates were analyzed for phosphorylated Akt and mTOR. Two-way ANOVA was performed to calculate statistical significance. Data are mean ± SEM. \**P* \< 0.05 vs. FBS(+) 30 min Ex-4(−).](jat-26-183-g004){#F4}

Exendin-4 Attenuates Cell Cycle Progression in VSMCs
----------------------------------------------------

Because NOR1 regulates VSMC proliferation by accelerating G1--S phase during cell cycle progression, as we reported previously^[@bib18])^, we next examined whether Ex-4 attenuates cell cycle progression in human VSMCs. As shown in **[Fig. 5](#F5){ref-type="fig"}**, G1--S phase and G2/M phase were induced by serum stimulation in human VSMCs. Furthermore, 10 nM Ex-4 pretreatment significantly attenuated cell cycle progression induced by serum (**[Table 3](#T3){ref-type="table"}**), suggesting that Ex-4 inhibits VSMC proliferation by attenuating cell cycle progression. Next, we examined whether Ex-4 regulated cell cycle regulators. As shown in **[Fig. 4C](#F4){ref-type="fig"}**, serum-induced degradation of p27 Kip, a major negative regulator of G1--S phase entry, was significantly inhibited by Ex-4 treatment. In addition, S-phase kinase-associated protein 2 (Skp2), which is the ubiquitin ligase of p27 Kip, was induced by serum stimulation and resulted in p27 kip degradation. Interestingly, Ex-4 significantly decreased Skp2 gene expression after serum stimulation (**[Fig. 5D](#F5){ref-type="fig"}**).

![Effect of Ex-4 on FBS-induced cell cycle progression in human aortic SMCs evaluated by flow cytometry.\
Serum-deprived human aortic SMCs were preincubated with vehicle or 10 nM Ex-4 for 12 h and stimulated with 10% FBS for 30 h. (A) Representative cell cycle distribution. (B) Values are expressed as the percentage of cells in each phase to the total cells. Statistical significance was calculated using unpaired *t*-tests. Data are mean ± SEM. \**P* \< 0.05 vs. FBS(+) Ex-4(−). (C) Serum-deprived human aortic SMCs were preincubated with vehicle or 10 nM Ex-4 for 12 h and stimulated with 10% FBS for the indicated times. p27 Kip1 protein expression was analyzed by western blotting. Two-way ANOVA was performed to calculate statistical significance. Data are mean ± SEM. \**P* \< 0.05 vs. FBS(+) Ex-4(−) (D) FBS-induced Skp2 mRNA expression was analyzed at the indicated times after FBS stimulation with vehicle or 10 nM Ex-4 pretreatment by qRT-PCR. Two-way ANOVA was performed to calculate statistical significance. Data are mean ± SEM. \**P* \< 0.05 vs. FBS(+) Ex-4(−)](jat-26-183-g005){#F5}

###### Cell cycle distribution of human vascular smooth muscle cells with or without exendin-4 (Ex-4) treatment

              Control      Ex-4         Control      Ex-4
  ----------- ------------ ------------ ------------ -------------------------------------------
  G0/G1 (%)   91.2 ± 0.5   91.6 ± 1.3   70.3 ± 2.8   77.5 ± 2.7
  S (%)       5.6 ± 0.3    3.9 ± 0.2    23.7 ± 1.4   16.5 ± 2.5[\*](#tf3){ref-type="table-fn"}
  G2/M (%)    4.9 ± 0.5    5.8 ± 0.2    13.5 ± 0.7   9.4 ± 1.3[\*](#tf3){ref-type="table-fn"}

One-way ANOVA was performed to calculate statistical significance. Data are expressed as the mean ± SEM.

FBS, fetal bovine serum.

*P* \< 0.05 compared with the Control FBS(+).

Exendin-4 Attenuates Neointima Formation After Vascular Injury in Diabetic Mice
-------------------------------------------------------------------------------

Because Ex-4 is used as a medication for patients with type 2 diabetes mellitus (T2DM), we next examined whether Ex-4 decreased neointima formation after vascular injury in mice fed high-fat diet, a model for insulin-resistant T2DM. As depicted in **[Fig. 6A](#F6){ref-type="fig"}**, elastic staining revealed the reduction of neointima formation after vascular injury. Quantitative analysis by measuring squares of the intima, media, and I/M ratio suggested that Ex-4 reduced neointima formation after vascular injury in a dose-dependent manner (**[Fig. 6B](#F6){ref-type="fig"}**). However, statistical significance was not observed (**[Table 4](#T4){ref-type="table"}**). As shown in **[Table 5](#T5){ref-type="table"}**, body weight and the plasma glucose level were significantly decreased by Ex-4 in a dose-dependent manner, suggesting that Ex-4 affected glucose metabolism.

![Neointima formation after vascular injury in control and Ex-4-treated mice fed high-fat diet.\
Endothelial denudation injuries were induced in the left femoral artery of control (*n* = 5) mice, Ex-4 low-dose (*n* = 5)-treated mice, and Ex-4 high-dose (*n* = 5)-treated mice. (A) Tissues were evaluated by staining with Elastica van Gieson to visualize the internal elastic lamina (magnification, ×200). (B) The area of the intima, media, and intima/media was calculated for each group. One-way ANOVA was performed to calculate statistical significance. Data are mean ± SEM.](jat-26-183-g006){#F6}

###### Neointima formation in exendin-4 (Ex-4)-treated mice fed a high-fat diet at 12 weeks of age following guidewire-induced endothelial denudation injury.

  ----------------------------------------------------------------------------
                   HFD                 HFD + Ex-4          HFD + Ex-4
  ---------------- ------------------- ------------------- -------------------
  Intima (µm^2^)   38212.6 ± 10921.1   32594.0 ± 7907.7\   18532.2 ± 6446.3\
                                       (*P* = 0.91)        (*P* = 0.35)

  Media (µm^2^)    12079.2 ± 1549.1    11684.0 ± 1615.7\   11072.0 ± 1235.9\
                                       (*P* = 0.90)        (*P* = 0.96)

  I/M ratio        2.78 ± 0.67         2.66 ± 0.57\        2.66 ± 0.57\
                                       (*P* = 0.99)        (*P* = 0.99)
  ----------------------------------------------------------------------------

Data are expressed as the mean ± SEM.

*P*-values refer to comparisons with the control.

###### Characteristics of exendin-4 (Ex-4)-treated mice fed a high-fat diet at 12 weeks of age following guidewire-induced endothelial denudation injury.

                           HFD           HFD + Ex-4     HFD + Ex-4
  ------------------------ ------------- -------------- ----------------------------------------------------------------------------
  Body weight (g)          29.1 ± 0.4    28.9 ± 0.5     25.7 ± 0.8[\*](#tf4){ref-type="table-fn"}, [\#](#tf5){ref-type="table-fn"}
  Plasma glucose (mg/dl)   158.2 ± 4.2   126.4 ± 12.3   119.4 ± 4.2[\*](#tf4){ref-type="table-fn"}
  Serum insulin (ng/ml)    1.07 ± 0.21   0.60 ± 0.14    0.56 ± 0.09

One-way ANOVA was performed to calculate statistical significance. Data are expressed as the mean ± SEM.

*P* \< 0.05 compared with the control.

*P* \< 0.05 compared with low-dose Ex-4.

Following experiments using non-diabetic normal mice, we counted cells in the neointima and media areas. As shown in **[Fig. 7A](#F7){ref-type="fig"}** shows, the neointima was completely occupied by VSMCs, and the cell number in the neointima and I/M ratio were decreased dose-dependently, although statistical significance was not observed. For further investigation, we performed immunohistochemistry of NOR1 and PCNA. As shown in **[Fig. 7C](#F7){ref-type="fig"}**, Ex-4 decreased NOR1 expression and PCNA-positive proliferating cells. Furthermore, cell counting revealed that the Ex-4-induced reductions of NOR1 expression and PCNA-positive proliferating cells were significant and dose dependent (**[Fig. 7D, E](#F7){ref-type="fig"}**). These data suggested that Ex-4 decreased NOR1 expression and VSMC proliferation *in vivo*, even in diabetic model mice.

![Ex-4 suppresses cell growth after vascular injury and expression of NOR1 and PCNA in VSMCs under high-fat diet feeding.\
(A) Sections were subjected to immunohistochemistry for *α*SMA (red) and counterstained with DAPI to visualize nuclei (blue). Magnification, ×630. (B) Total cell count of the intima and media. One-way ANOVA was performed to calculate statistical significance. Data are mean ± SEM. (C) Representative immunofluorescence image of injured femoral arteries showing NOR1 (cyan) and PCNA (green). Magnification, ×630. (D) (E) NOR1- and PCNA-positive cells were quantified by analyzing the fraction of stained cells to the total number of nuclei (Control, *n* = 5; Ex-4 LD, *n* = 5; and Ex-4 HD, *n* = 5). Values are expressed as the percentage of positive cells. One-way ANOVA was performed to calculate statistical significance. \**P* \< 0.05 vs. control, \*\**P* \< 0.01 vs. control.](jat-26-183-g007){#F7}

Discussion
==========

The present study suggested that GLP-1R agonist Ex-4 attenuates neointima formation after vascular injury and VSMC proliferation associated with the reduction of NOR1 expression in both diabetic and non-diabetic model mice. Furthermore, the molecular mechanism by which Ex-4 attenuates VSMC proliferation was the reduction of serum-induced Skp2 gene expression, resulting in inhibition of cell cycle progression. As we reported previously^[@bib7],\ [@bib8])^, the direct vascular-protective effect of incretin has been a recent focus. Reports from other groups confirmed the hypothesis that incretins, particularly GLP-1, may have direct anti-atherosclerotic and vascular-protective effects independent of their glucose-lowering effect^[@bib20],\ [@bib21])^. Furthermore, current evidence based on large scale clinical trials in patients with type 2 diabetes using GLP-1R agonists suggest vascular-protective effects of GLP-1 in animal models as well as patients with type 2 diabetes^[@bib22],\ [@bib23])^. VSMC proliferation contributes to not only primary atherosclerotic lesions but also vascular stenosis after vascular injury and coronary angioplasty. In addition, several pathological backgrounds in the diabetic state may accelerate VSMC pathogenesis directly and indirectly^[@bib24])^. Therefore, the inhibition of smooth muscle cell proliferation by anti-diabetic agents could be beneficial to patients with type 2 diabetes. Among vascular cells, VSMCs abundantly express GLP-1R^[@bib8],\ [@bib21])^ and important targets for vascular-protective effects by GLP-1. A GLP-1R agonist attenuates neointima formation after vascular injury^[@bib8],\ [@bib21])^, which has a direct effect on VSMCs but not the activation of re-endothelialization after endothelial denudation^[@bib25])^, suggesting that the vascular-protective effect of GLP-1 mainly occurs in VSMCs. Some mechanisms by which GLP-1 attenuates VSMC pathogenesis have been reported, such as inhibition of RAS-related C3 botulinus toxin substrate 1 (Rac1) activation^[@bib26])^ and enhancement of endoplasmic reticulum-mitochondria coupling^[@bib27])^. Furthermore, some data suggest that adiponectin is a molecular target through which incretin protects against vascular diseases^[@bib28],\ [@bib29])^. In addition to these mechanisms, we provide a novel mechanism by which GLP-1 attenuates NOR1 expression in VSMCs in the present study.

NOR1 is a well-elucidated orphan nuclear receptor that regulates VSMC proliferation^[@bib15])^. A recent study suggested that NOR1 expression in VSMCs is regulated via epigenetic modification^[@bib30])^ and microRNA-638 expression^[@bib31])^. Furthermore, NOR1 phosphorylation by DNA-dependent protein kinase reportedly modulates VSMC proliferation^[@bib32])^. Despite several known regulation mechanisms of NOR1 expression and its activation, there has been no report suggesting NOR1 regulation in VSMCs by clinical medications, such as antihypertensive drugs, anti-diabetic agents, and anticoagulants. This is the first report suggesting that an antidiabetic agent and a GLP-1R agonist, attenuates NOR1 expression in VSMCs. In our previous reports using mouse VSMCs, we investigated two main targets of NOR1 that accelerate VSMC proliferation: Cyclin D1^[@bib18])^ and Skp2^[@bib19])^. In the present study using human VSMCs, Cyclin D1 expression was not changed by Ex-4-induced NOR1 reduction (data not shown). However, Skp2 gene expression was significantly decreased (**[Fig. 5D](#F5){ref-type="fig"}**), resulting in the upregulation of p27 Kip protein expression (**[Fig. 5C](#F5){ref-type="fig"}**) and attenuation of cell cycle progression (**[Fig. 5A, B](#F5){ref-type="fig"}**). These data suggest that the main target of NOR1 related to cell cycle progression is Skp2 in human VSMCs.

In the present study, we found that Ex-4 inhibited serum-induced ERK-MAPK phosphorylation (**[Fig. 4A](#F4){ref-type="fig"}**). Interestingly, we previously reported the same Ex-4 effect in the prostate cancer cell line LNCaP^[@bib9])^. Both VSMCs and cancer cells are pathologically proliferating and growing cells. Ex-4 may regulate pathological cell proliferation and growth as a tissue-protective effect. In the present study, we investigated Ex-4 actions in VSMCs. However, the main clinical target of Ex-4 as an incretin therapy for patients with type 2 diabetes is pancreatic *β* cells to stimulate glucose-dependent insulin secretion^[@bib33])^. Interestingly, a report has suggested an interaction between incretin and NOR1 in pancreatic *β* cells^[@bib34])^. Therefore, further elucidation of the interaction between incretin and NOR1 is required.

In the present study, all our experiments were conducted using Ex-4 as a GLP-1R agonist, which is clinically available as Exenatide. Although the present study and our previous studies^[@bib7],\ [@bib8])^ demonstrated the vascular-protective effect of Ex-4, a recent large scale randomized control trial using Exenatide, the EXSCEL study, could not demonstrate significant reduction compared with the placebo control^[@bib35])^, although other GLP-1R agonists did improve cardiovascular outcome^[@bib22],\ [@bib23])^. The EXSCEL study has a shorter study period and higher baseline HbA1c than the LEADER trial using liraglutide^[@bib22])^ (3.8 years vs. 3.2 years and 8.0% vs. 8.7%, respectively). In addition, sulfonylureas and insulin use were profoundly increased in the placebo group of the LEADER trial, although GLP-R agonists, sodium-glucose cotransporter 2 inhibitors, and DPP-4 inhibitors use were increased in the placebo group of the EXSCEL trial^[@bib35])^. These clinical differences may contribute to the different cardiovascular outcomes between the LEADER trial and EXSCEL study. In fact, the low dose of Ex-4 in the present study is the pharmacological dose, as discussed in our previous reports^[@bib7],\ [@bib9],\ [@bib36])^, suggesting that some beneficial clinical cardiovascular effect could be expected from the present study. However, different individual effects on cardiovascular systems by GLP-1R agonists are also suggested^[@bib37])^. Further clinical trials and basic experiments are required.

Conclusion
==========

Ex-4 attenuates neointima formation after vascular injury and VSMC proliferation possibly by inhibiting NOR1 and Skp2 expression. In addition, Ex-4 attenuates ERK-MAPK and CREB phosphorylations as well as G1--S phase entry during cell cycle progression in VSMCs. The reduction of NOR1 expression could be key in preventing cardiovascular events and atherosclerosis in patients with type 2 diabetes using incretin therapy.
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